Complications and the Influence of COVID-19 on Myocardial Function and Exercise Capacity

NCT ID: NCT04828629

Last Updated: 2024-04-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-12-23

Study Completion Date

2025-01-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The subject of the study is the impact of COVID-19 on the indicators of myocardial efficiency and exercise capacity. As a result of the observed dependencies, it will be possible to start an appropriate diagnostic procedure early, select personalized treatment and develop a model of cardiological care for people with a history of SARS-CoV-2 infection and improve the quality and extend their life.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

About 100 adult patients hospitalized in the Department of Cardiology and Congenital Heart Diseases of Adults who had recovered from COVID-19 will be included in the study. Selected prognostic factors will be analyzed, among others: demographic data of the patient, physical examination, symptoms, co-morbidities, results of selected laboratory tests, lung imaging (X-ray or computed tomography) selected electrocardiographic and echocardiographic data, patient's cooperation with the doctor, treatment applied, parameters in the spiroergometric study, body mass analysis. One year after inclusion in the study, a control hospitalization will be performed. The same factors will be analyzed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Covid19 Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Identification of prognostic factors in patients who have recovered from COVID-19

Selected prognosis factors will be analyzed in patients who have recovered from COVID-19

Diagnostic tests

Intervention Type DIAGNOSTIC_TEST

Selected prognostic factors will be analyzed, among others: demographic data of the patient, physical examination, symptoms, co-morbidities, results of selected laboratory tests, lung imaging (X-ray or computed tomography) selected electrocardiographic and echocardiographic data, patient's cooperation with the doctor, treatment applied, parameters in the spiroergometric study, body mass analysis.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Diagnostic tests

Selected prognostic factors will be analyzed, among others: demographic data of the patient, physical examination, symptoms, co-morbidities, results of selected laboratory tests, lung imaging (X-ray or computed tomography) selected electrocardiographic and echocardiographic data, patient's cooperation with the doctor, treatment applied, parameters in the spiroergometric study, body mass analysis.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age equal to or older than 18 years
* infection with the SARS-CoV-2 in past medical history
* current hospitalization

Exclusion Criteria

* severe hypertension;
* unstable angina;
* acute pulmonary embolism;
* decompensated heart failure;
* recent myocardial infarction;
* unstable heart rhythm disturbances;
* acute myocarditis or pericarditis;
* active endocarditis;
* advanced atrioventricular block;
* diagnosis of cardiomyopathy (hypertrophic, dilated, restrictive, peripartum, arrhythmogenic)
* lysosomal storage disorders
* severe hyper- and hypothyroidism
* pregnancy and lactation
* chronic kidney disease (IV, V stadium according to NKF) and dialysis treatment
* documented neoplastic process
* the patient's inability to cooperate and/or provide informed consent to participate in a research
* alcohol and drug abuse
* active autoimmune disease
* treatment using immunosuppressants, cytostatic drugs, glucocorticosteroids, or antiretroviral drugs
* a history of bone marrow transplant or other organ transplant, treatment with blood products within the last 6 months
* active systemic infection
* HBV, HCV or HIV carrier or positive for HbS antigen or antibodies to HCV
* surgery or serious injury within the last month
* patients who did not express their informed consent to participate in the study
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Polish Mother Memorial Hospital Research Institute

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Agata Bielecka-Dabrowa

Role: STUDY_CHAIR

Heart Failure Unit; Department of Cardiology and Congenital Diseases of Adults, PMMHRI

Maciej Banach

Role: STUDY_CHAIR

Heart Failure Unit; Department of Cardiology and Congenital Diseases of Adults, PMMHRI

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Heart Failure Unit; Department of Cardiology and Congenital Diseases of Adults, Polish Mother's Memorial Hospital Research Institute

Lodz, Polska, Poland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Poland

References

Explore related publications, articles, or registry entries linked to this study.

Gryglewska-Wawrzak K, Sakowicz A, Banach M, Bytyci I, Bielecka-Dabrowa A. Diagnostic Usefulness of Spiroergometry and Risk Factors of Long COVID in Patients with Normal Left Ventricular Ejection Fraction. J Clin Med. 2023 Jun 20;12(12):4160. doi: 10.3390/jcm12124160.

Reference Type DERIVED
PMID: 37373853 (View on PubMed)

Gryglewska-Wawrzak K, Sakowicz A, Banach M, Maciejewski M, Bielecka-Dabrowa A. Factors of Persistent Limited Exercise Tolerance in Patients after COVID-19 with Normal Left Ventricular Ejection Fraction. Biomedicines. 2022 Dec 15;10(12):3257. doi: 10.3390/biomedicines10123257.

Reference Type DERIVED
PMID: 36552013 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PMMHRI-BCO.75/2020

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.